|
|
|
|
| LEADER |
01680nam a2200337 u 4500 |
| 001 |
EB001872301 |
| 003 |
EBX01000000000000001035672 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190824 r ||| eng |
| 130 |
0 |
|
|a CADTH Canadian Drug Expert Committee recommendation. AbobotulinumtoxinA (Dysport therapeutic--Ipsen Biopharmaceuticals Canada, Inc.) (August 2018)
|
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: AbobotulinumtoxinA (Dysport therapeutic--Ipsen Biopharmaceuticals Canada, Inc.)
|h Elektronische Ressource
|b indication : for the symptomatic treatment of lower limb spasticity (LLS) in pediatric patients two years of age and older
|
| 246 |
3 |
1 |
|a AbobotulinumtoxinA (Dysport therapeutic--Ipsen Biopharmaceuticals Canada, Inc.)
|
| 246 |
3 |
1 |
|a Drug reimbursement recommendation AbobotulinumtoxinA (Dysport Therapeutic)
|
| 250 |
|
|
|a Version: Final
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2018, August 2018
|
| 300 |
|
|
|a 1 PDF file (8 pages)
|
| 653 |
|
|
|a Insurance, Health, Reimbursement
|
| 653 |
|
|
|a Child
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Muscle Spasticity / drug therapy
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Botulinum Toxins, Type A / therapeutic use
|
| 653 |
|
|
|a Lower Extremity
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK540040
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|